Metal Ion-Loaded Nanofibre Matrices for Calcification Inhibition in Polyurethane Implants
Source abstract
Abstract
Pathologic calcification leads to structural deterioration of implant materials via stiffening, stress cracking, and other structural disintegration mechanisms, and the effect can be critical for implants intended for long-term or permanent implantation. This study demonstrates the potential of using specific metal ions (MI)s for inhibiting pathological calcification in polyurethane (PU) implants. The hypothesis of using MIs as anti-calcification agents was based on the natural calcium-antagonist role of Mg2+ ions in human body, and the anti-calcification effect of Fe3+ ions in bio-prosthetic heart valves has previously been confirmed. In vitro calcification results indicated that a protective covering mesh of MI-doped PU can prevent calcification by preventing hydroxyapatite crystal growth. However, microstructure and mechanical characterisation revealed oxidative degradation effects from Fe3+ ions on the mechanical properties of the PU matrix. Therefore, from both a mechanical and anti-calcification effects point of view, Mg2+ ions are more promising candidates than Fe3+ ions. The in vitro MI release experiments demonstrated that PU microphase separation and the structural design of PU-MI matrices were important determinants of release kinetics. Increased phase separation in doped PU assisted in consistent long-term release of dissolved MIs from both hard and soft segments of the PU. The use of a composite-sandwich mesh design prevented an initial burst release which improved the late (>20 days) release rate of MIs from the matrix.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Dental materials and restorations · Orthopaedic implants and arthroplasty
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Future Fibres Research and Innovation Centre, Institute for Frontier Materials, Deakin University, Geelong, VIC 3216, Australia
School of Textile Science and Engineering, Wuhan Textile University, Wuhan 430073, China
References (75)
Show source-provided references
1. Changes in polyurethane calcification due to antibiotics10.1111/j.1525-1594.1996.tb04536.x ↗
2. Determinants of Pathologic Mineralization10.1097/01.bor.0000209431.59226.46 ↗
3. Biology of calcification in vascular cells: Intima versus media10.1007/PL00002027 ↗
4. Calcified deposit formation in intimal thickenings of the human aorta10.1016/0021-9150(95)05588-N ↗
5. The role of material surface chemistry in implant device calcification: A hypothesis
6. Biomaterial-associated calcification: Pathology, mechanisms, and strategies for prevention
7. Buddy, D.R. (2013). Chapter II.4.5—Pathological Calcification of Biomaterials. Biomaterials Science, Academic Press. [3rd ed.].
8. Pathology of explanted polytetrafluoroethylene vascular grafts10.1016/j.carpath.2010.06.005 ↗
9. Long term performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement model10.1016/j.biomaterials.2011.09.024 ↗
10. Polytetrafluoroethylene graft calcification in patients with surgically repaired congenital heart disease: Evaluation using multidetector-row computed tomography10.1016/j.ahj.2007.01.035 ↗
11. The role of vascular calcification in inducing fatigue and fracture of coronary stents10.1002/jbm.b.31911 ↗
12. Elemental composition, morphology and mechanical properties of calcified deposits obtained from abdominal aortic aneurysms10.1016/j.actbio.2006.05.003 ↗
13. Genetics in Arterial Calcification: Pieces of a Puzzle and Cogs in a Wheel10.1161/CIRCRESAHA.111.247965 ↗
14. Vascular Calcification Mechanisms10.1097/01.ASN.0000145894.57533.C4 ↗
15. The pulsewave reflections model: Exploring for a fundamental mechanism of cardiovascular calcification10.1016/j.mehy.2006.12.059 ↗
16. Mechanisms of inhibition of calcification10.1097/00003086-198910000-00038 ↗
17. Metallic ions as therapeutic agents in tissue engineering scaffolds: An overview of their biological applications and strategies for new developments
18. Electrospun Nanofibrous Polyurethane Membrane as Wound Dressing10.1002/jbm.b.10058 ↗
19. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer10.1016/S0168-3659(03)00342-0 ↗
20. Biomimetic polyurethane—Based fibrous scaffolds10.1016/j.matlet.2015.12.117 ↗
21. Synthesis and structure–property relationship of polyester-urethanes and their evaluation for the regeneration of contractile tissues10.1016/j.reactfunctpolym.2013.01.006 ↗
22. Metal ion release kinetics from nanoparticle silicone composites10.1016/j.jconrel.2011.05.023 ↗
23. Silver ion release from polymethyl methacrylate silver nanocomposites
24. Kinetic aspects of the silver ion release from antimicrobial polyamide/silver nanocomposites10.1007/s00339-008-4434-1 ↗
25. Calcite growth-rate inhibition by fulvic acid and magnesium ion—Possible influence on biogenic calcite formation10.1016/j.jcrysgro.2011.12.069 ↗
26. Does iron inhibit calcification during atherosclerosis?10.1016/j.freeradbiomed.2012.07.014 ↗
27. Inhibition of bioprosthesis calcification due to synergistic effect of Fe/Mg ions to polyethylene glycol grafted bovine pericardium10.1106/0JE0-M473-XATE-6EJD ↗
28. Magnesium transport in hypertension10.1016/j.pathophys.2007.09.005 ↗
29. Magnesium and ischemic heart disease: A review of epidemiological, experimental, and clinical evidences
30. Role of magnesium in genomic stability10.1016/S0027-5107(01)00074-4 ↗
31. Physiological and pathophysiological role of magnesium in the cardiovascular system: Implications in hypertension10.1097/00004872-200018090-00003 ↗
32. Magnesium: Nature’s physiologic calcium blocker10.1016/0002-8703(84)90572-6 ↗
33. Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum10.1007/s00109-010-0596-3 ↗
34. Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat—Differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali10.1016/S0753-3322(02)00343-8 ↗
35. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients10.5414/CNP68222 ↗
36. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: A literature review10.1177/089686080602600315 ↗
37. Serum magnesium level and arterial calcification in end-stage renal disease10.1038/ki.1987.222 ↗
38. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis10.1007/s11255-008-9410-3 ↗
39. Mitral annular calcifications in haemodialysis patients: A possible protective role of magnesium10.1093/ndt/12.9.2036 ↗
40. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner10.1093/ndt/gfr321 ↗
41. The role of magnesium binders in chronic kidney disease10.1111/j.1525-139X.2007.00307.x ↗
42. Beneficial effects of magnesium in chronic renal failure: A foe no longer10.1007/s11255-008-9510-0 ↗
43. Magnesium deficiency and hypertension: Correlation between magnesium-deficient diets and microcirculatory changes in situ10.1126/science.6701524 ↗
44. Effect of magnesium on lipid-induced calcification: An in vitro model for bone mineralization10.1007/BF02408533 ↗
45. Calcium phosphate formation in vitro: II. Effects of environment on amorphous-crystalline transformation10.1016/0003-9861(70)90072-X ↗
46. Factors affecting the solubility of calcium pyrophosphate dihydrate crystals10.1172/JCI108239 ↗
47. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification10.1159/000334742 ↗
48. Infrared Studies of Segmented Polyurethan Elastomers. I. Hydrogen Bonding10.1021/ma60017a021 ↗
49. Degradation studies on segmented polyurethanes prepared with HMDI, PCL and different chain extenders10.1016/j.actbio.2009.12.010 ↗
50. An FTIR–ATR investigation of in vivo poly(ether urethane) degradation10.1002/app.1992.070460202 ↗
51. The cation-chelation mechanism of metal-ion sorption by polyurethanes10.1016/0039-9140(82)80118-5 ↗
52. Polyurethane anionomers containing metal ions with antimicrobial properties: Thermal, mechanical and biological characterization10.1016/j.actbio.2010.03.042 ↗
53. Dexamethasone eluting biodegradable polymeric matrix coated stent for intravascular drug delivery10.1016/j.cherd.2010.03.007 ↗
54. Polyurethane-based drug delivery systems10.1016/j.ijpharm.2013.04.063 ↗
55. Higuchi equation: Derivation, applications, use and misuse10.1016/j.ijpharm.2011.03.051 ↗
56. Modeling of diffusion controlled drug delivery10.1016/j.jconrel.2011.10.006 ↗
57. Characterization and anticalcification effects of implantable polyurethane matrices containing amorphous dispersion of bisphosphonic acid10.1016/0267-6605(91)90007-3 ↗
58. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-110.1002/jps.21331 ↗
59. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir10.1016/j.ejps.2009.11.007 ↗
60. Novel Design of Microreservoir-Dispersed Matrices for Drug Delivery Formulations: Drug Release from Polybutadiene- and Poly (ethylene oxide)-Based Segmented Polyurethanes in Relation to Their Microdomain Structures10.1177/088391158800300202 ↗
61. Development of a new in vitro model for studying implantable polyurethane calcification10.1016/0142-9612(91)90008-X ↗
62. Effect of Mechanical Deformation on in Vitro Calcification of Segmented Polyurethane
63. Controlled release of ferric-magnesium ions from chitosan/polyethylene vinyl acetate comatrix for preventing pericardial calcification10.1080/107175499267048 ↗
64. Inhibition of in vitro calcium phosphate precipitation in presence of polyurethane via surface modification and drug delivery10.1002/jab.770050310 ↗
65. The anti-calcification potential of a silsesquioxane nanocomposite polymer under in vitro conditions: Potential material for synthetic leaflet heart valve10.1016/j.actbio.2010.06.015 ↗
66. A novel in vitro assessment of tissue valve calcification by a continuous flow type method10.1046/j.1525-1594.2000.06482-2.x ↗
67. Calcification and fatigue failure in a polyurethane heart valve10.1016/0142-9612(95)93255-C ↗
68. Calcifications in human osteoarthritic articular cartilage: Ex vivo assessment of calcium compounds using XANES spectroscopy10.1107/S0909049511006984 ↗
69. In vitro calcification of UHMWPE/PU composite membrane10.1016/S0928-4931(02)00025-5 ↗
70. Assessing the resistance to calcification of polyurethane membranes used in the manufacture of ventricles for a totally implantable artificial heart10.1002/(SICI)1097-4636(1999)48:5<648::AID-JBM8>3.0.CO;2-6 ↗
71. Coury, A.J., Cahalan, P.T., Schultz, E.L., and Stokes, K.B. (May, January 27). In Vitro Aging of Implantable polyurethanes in Metal Ion Solutions. Proceedings of the 2nd Transactions World Congress on Biomaterials, Washington, DC, USA.
72. Gebelein, C. (1987). Metal Catalyzed Oxidative Degradation of Implanted Polyurethane Devices. Advances in Biomedical Polymers, Springer.10.1007/978-1-4613-1829-3 ↗
73. Gebelein, C. (1987). Metal Ion Complexation of Poly(Ether)Urethanes. Advances in Biomedical Polymers, Springer.10.1007/978-1-4613-1829-3 ↗
74. The in vivo auto-oxidation of polyether polyurethane by metal ions10.1163/156856290X00062 ↗
75. Biocompatibility of poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) with bone marrow mesenchymal stem cells10.1016/j.actbio.2008.09.021 ↗